PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer
| Image |  |
|---|---|
| Description | scientific article published on 23 September 2019 |
| Author/s |
author: Steven J Isakoff David B Solit Paula González Ericsson Justin M. Balko Eric Winer Luigi Formisano |
| Publication date | September 23, 2019 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |